Quick Summary
Investment Cure Research is a SEBI registered Research Analyst run by Saurab Jain, INH000012838, active since August 2023 and based in Indore, Madhya Pradesh. His own compliance audit status discloses that the RA “has not followed the compliance” with respect to the SHE Box portal requirement during F.Y. 2024-25. His terms state clients acknowledge “there is no recourse to claim any losses” incurred on investments made based on the research reports. His annual complaint table also stops at FY2024-25, with no year published since, despite the registration continuing to operate.
Investment Cure Research operates under SEBI Research Analyst registration INH000012838, held by Saurab Jain, active since 31 August 2023, based in Indore, Madhya Pradesh.
The registration is genuine.
His own annual compliance audit status discloses something worth reading carefully: a documented lapse in SHE-Box portal compliance for the most recent financial year audited.
This page works through the registration, that disclosed lapse, the pricing against the SEBI cap, the complaint data, and a terms clause that goes further than most firms’ liability language.
Investment Cure Research Review
The firm offers three services covering Equity and F&O: GAMA Cash for cash intraday trading, Theta Index Option for Nifty and Bank Nifty index options, and Beta Future for futures-based recommendations.
Saurab Jain’s own site states he has more than 12 years of experience in technical and derivative analysis, without further supporting detail.
The disclosure document states the RA has no associates, and reports no SEBI penalties, directions, or material pending litigation as of the document’s date.
No social media profiles are linked on the site at all, which at least means there’s no promotional social content elsewhere to independently check against the firm’s own claims.
None of this establishes wrongdoing.
Where conduct genuinely crosses a line, the escalation route is covered further down this page.
Saurab Jain, Proprietor Of Investment Cure Research
The registration is held by an individual.
| Detail | Information |
|---|---|
| Name | Saurab Jain, Proprietor Investment Cure Research |
| SEBI Registration Number | INH000012838 |
| Validity | 31 August 2023, Perpetual |
| Address | 175 Tilak Nagar, Flat No. 201, Indra Apartment, Indore, Madhya Pradesh 452001 |
| Contact Person | Saurab Jain |
| [email protected] |
The INH prefix marks a Research Analyst. It permits research and recommendations to a subscriber base. It does not permit personalised advice, trade execution, or portfolio management.
Saurab Jain is listed as both the Compliance Officer and Grievance Officer, with the same phone number and email for both.
For an individual registration, this is common and not itself irregular.
What Does Saurab Jain‘s Own Compliance Audit Disclose?
This is the most distinctive finding on this page.
SEBI requires an annual compliance audit for Research Analysts, conducted by a Chartered Accountant or Company Secretary under Regulation 25(3).
The audit status published on the site records 2023-24 as done, with no remarks.
For 2024-25, it states the audit was completed, but with a specific note: the RA “has not followed the compliance” with respect to the SHE Box portal requirement during F.Y. 2024-25.
The SHE-Box portal is the government’s centralised complaint management system for sexual harassment at the workplace, tied to POSH Act obligations.
A documented gap here is a real compliance finding, stated by the firm’s own audit rather than inferred from anything external.
This doesn’t tell you what specifically wasn’t followed, or whether it’s been corrected since.
Ask the firm directly for the current status and what remediation, if any, has taken place.
What Does Investment Cure Research’s Terms & Conditions Say About Investment Losses?
The terms state plainly that a client acknowledges “there is no recourse to claim any losses” incurred on investments made based on the research reports.
This is broader than a standard risk disclaimer.
Most firms state they aren’t liable for losses arising from market movements. This clause states there is no recourse at all, full stop.
SEBI’s own regulatory framework still provides recourse mechanisms regardless of what a firm’s own terms claim, through SCORES, structured conciliation, and arbitration.
A private terms clause doesn’t override your standing to use those channels.
The same client obligations section separately states clients may not share research reports with third parties without the RA’s consent, and must keep contact details updated with the firm at all times.
Investment Cure Research Pricing and the ₹1,51,000 SEBI Fee Cap
The pricing itself stays under the ceiling.
A Research Analyst may charge a maximum of ₹1,51,000 per annum per family.
Published Price List
All three services share an identical price structure.
| Cycle | Price |
|---|---|
| Monthly | ₹11,000 |
| Quarterly | ₹25,000 |
Annualised, the monthly cycle comes to ₹1,32,000. Every plan, on either cycle, stays under the limit.
Combining Services Is Where The Arithmetic Changes
Three services, priced identically, cover genuinely different market segments.
Holding all three at the monthly rate comes to ₹3,96,000 a year, well over the ceiling.
If you subscribe to more than one Investment Cure Research service, add the totals together before assuming you’re within the SEBI cap.
Pricing Page Doesn’t Say What You’re Actually Buying
Beyond the fee itself, the pricing section states only the amount and duration, without specifying how many recommendations are included, how frequently they arrive, or through what channel.
Clicking “Join Now” on any of the three services currently leads nowhere, rather than to a working enrolment or payment page.
If you want to subscribe, you’ll need to contact the firm directly rather than complete anything through the site itself.
What Does Investment Cure Research’s Complaint Data Show?
Investment Cure Research’s complaint disclosures provide a limited picture of its grievance history, with the available figures spread across annual and monthly reporting periods.
The key point is what the published numbers show and what they leave unexplained.
Annual Table
| Financial Year | Received | Resolved | Pending |
|---|---|---|---|
| 2020-21 | 0 | 0 | 0 |
| 2021-22 | 0 | 0 | 0 |
| 2022-23 | 0 | 0 | 0 |
| 2023-24 | 0 | 0 | 0 |
| 2024-25 | 3 | 3 | 0 |
Three complaints in FY2024-25, all resolved, nothing pending. That’s a genuinely light record, and it’s worth reading that way.
The disclosure gives no detail on what these three complaints actually concerned.
The Table Simply Stops; It Doesn’t Contradict Anything
The annual table has no row for FY2025-26 or FY2026-27, despite the registration continuing to operate through both.
The separate monthly table, covering August 2025 through August 2026, shows zero complaints throughout.
That window falls entirely within the two years missing from the annual table.
Read together, these two tables don’t actually disagree with each other numerically.
The monthly table’s zeros are consistent with the years the annual table simply never got around to adding.
The real issue is that the annual disclosure hasn’t been extended to cover roughly eighteen months of the firm’s operating history, not that the two tables tell conflicting stories.
On The Grievance Timeline
The Investor Charter states the RA will redress a grievance “not later than 21 days,” and separately notes a complaint can be escalated to SCORES “if not resolved within 30 days.”
Read as two separate, sequential thresholds, these aren’t necessarily in conflict: a 21-day internal target, followed by a 30-day outer window before SCORES escalation becomes available.
If you’re unsure which applies to your own situation, ask the firm to confirm the timeline directly rather than assume either figure on its own.
Which Saurab Jain‘s Marketing Claims Need a Closer Look?
The site describes its services as “comprehensive,” built on “advanced technology,” with “exceptional customer support,” none of which is explained with specific detail.
The 12+ years of experience claim is prominently displayed without any supporting detail behind it either.
None of this amounts to an explicit guarantee of returns.
It’s the kind of language a compliance review would ordinarily flag for lacking the substance behind it.
How to Raise a Concern With Saurab Jain?
Given the specific findings above, particularly the “no recourse” clause and the disclosed SHE-Box lapse, a complaint here has firmer ground than a dispute over research quality alone.
Get the current status of the SHE-Box compliance gap in writing if it matters to your decision to subscribe, and don’t treat the “no recourse” clause as the final word on your options if something goes wrong.
Send your grievance to the RA’s email ID and keep the sent record.
If that doesn’t resolve things, the regulator’s own channels take over next.
A complaint can be lodged on the SEBI SCORES complaint portal once you’ve documented what you were told and what you paid.
From there, unresolved matters move into conciliation through the SMART ODR portal.
Beyond that sits share market arbitration, which produces a binding award rather than a response you simply have to accept.
Our full guide on how to complaint against a SEBI-registered research analyst walks through sequencing a case like this properly.
Told there’s no recourse for a losing call?
We check that claim against what SEBI’s own framework actually provides, and put your case on record in a form the analyst has to respond to. Register with us for a free read on your situation.
Disclaimer
This page is based on Investment Cure Research’s own published material and alleges no wrongdoing since no SEBI order exists against the firm.
Verify all details at source before acting. This is research, not legal advice.
Conclusion
Saurab Jain’s Investment Cure Research holds a genuine SEBI registration, INH000012838, with pricing that stays comfortably under the SEBI cap on any single plan.
Two things deserve real attention.
His own compliance audit discloses a SHE-Box portal lapse for FY2024-25, and his terms state clients have no recourse for investment losses at all, language broader than the standard risk disclaimer most firms carry.
Before subscribing, ask for the current status of the compliance gap, and don’t accept the “no recourse” clause as removing your actual options under SEBI’s framework.
Report. Recover. Stay Fraud Free.
Frequently Asked Questions
Per the firm's own published disclosure, it's registered to Saurab Jain since August 2023, perpetual. Confirm it directly on SEBI's own register.
No. SEBI's own complaint and dispute resolution channels, SCORES, conciliation and arbitration, remain available regardless of what a firm's private terms state.
Not on any single plan. Holding all three services together at the monthly rate does cross the ceiling, so add your totals if you subscribe to more than one.
The site doesn't explain this. It leaves roughly eighteen months of the firm's operating history without an annual complaint figure, though the separate monthly table for that period shows no activity.
Add us as a preferred source on Google »
